상세 보기
Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
- Oh, Jieun;
- Joo, Kwon-Wook;
- Chin, Ho-Jun;
- Chae, Dong-Wan;
- Kim, Sung-Gyun;
- ... Huh, Wooseong;
- 외 7명
WEB OF SCIENCE
6SCOPUS
5초록
Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. This study investigated the efficacy of CERA for correcting anemia in Korean patients on dialysis. Patients (>= 18 yr) who were not receiving any ESAs for more than 8 weeks were randomly assigned to either intravenous CERA once every 2 weeks (n = 39) or epoetin beta thrice-weekly (n = 41) during a 24-week correction phase. Hemoglobin (Hb) response was defined as increase of Hb by at least 1 g/dL and Hb >= 11 g/dL without red blood cell (RBC) transfusion. Median dialysis duration was 1.7 (0.3-20.8) and 1.6 (0.4-13.8) yr in CERA and epoetin beta group, respectively. Hemoglobin response rate of CERA was 79.5% (95% confidence interval [CI], 63.5-90.7). As the lower limit of 95% CI was higher than pre-specified 60% response rate, it can be concluded that CERA corrected anemia (P < 0.05). Hb response rate of epoetin beta was 87.8% (95% CI, 73.8-95.9) (P = 0.37). Median time to response was 12 weeks in CERA and 10.3 weeks in epoetin beta (P = 0.03). It is suggested that once every 2 weeks administration of CERA is effective for correcting anemia in Korean patients on long-term hemodialysis with longer time-to-response than thrice weekly epoetin beta.
키워드
- 제목
- Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
- 저자
- Oh, Jieun; Joo, Kwon-Wook; Chin, Ho-Jun; Chae, Dong-Wan; Kim, Sung-Gyun; Kim, Soo Jin; Chung, Wookyung; Kim, Sejoong; Huh, Wooseong; Oh, Ha Young; Choi, Bum Soon; Yang, Chul-Woo; Kim, Suhnggwon
- 발행일
- 2014-01
- 유형
- Article
- 권
- 29
- 호
- 1
- 페이지
- 76 ~ 83
- 언어
- ENG
- 출판사
- 대한의학회
- 발행국가
- 대한민국
- 분량
- 8 페이지
- ISSN
- E 1598-6357
P 1011-8934